Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 15/20 | 0.58 |
| ▸ | PGR | P06401 | 12/20 | 0.58 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5526784 | 0.83 | NR3C1 (0.66) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL5524970 | 0.82 | NR3C1 (0.64) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL5521627 | 0.81 | NR3C1 (0.64) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL1634894 | 0.81 | NR3C1 (0.52) | NR3C1NR3C2PGR | |
| SCHEMBL5531550 | 0.79 | NR3C1 (0.63) | NR3C1NR3C2PGR | |
| SCHEMBL5523789 | 0.77 | NR3C1 (0.64) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL5523197 | 0.77 | NR3C1 (0.59) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL5528806 | 0.77 | NR3C1 (0.64) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL5520814 | 0.77 | NR3C1 (0.61) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL5524765 | 0.77 | NR3C1 (0.71) | NR3C1NR3C2PGRPDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268152-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | claimed |
| EP-1490317-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | claimed |
| WO-2003082787-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | claimed |
| US-7268152-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268152-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268152-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1490317-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003082787-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.